Pharmacy and Therapeutics (P & T) Committee

Meeting Agenda

December 1, 2016

Oakland/Hayward Conference Room

6:00PM-8:00PM

I) Call to order

II) Review and Approval of Agenda and Minutes
   a. 9-1-16 Meeting Minutes

III) Utilization Reviews and Recommendations
   a. Oral antihistamines
   b. Systemic contraceptives
   c. Rx Ophthalmic Preparations

IV) Class Reviews, Monographs and Recommendations
   a. Irritable Bowel Syndrome
   b. Benign Prostatic Hyperplasia
   c. Antineoplastics – Systemic Enzyme Inhibitor Agents
   d. Venclexta Monograph
   e. Opioids and opioid combinations
   f. Benzodiazepines

V) Medication Request Guidelines
   a. Step therapy protocol
   b. Specialty Biological Agents for Crohn’s
   c. Specialty Biological Agents for Ulcerative Colitis
   d. Specialty Biological Agents for Psoriatic Arthritis
   e. Specialty Biological Agents for Psoriasis
   f. Specialty Biological Agents for Polyarticular Juvenile Idiopathic Arthritis
   g. Specialty Biological Agents for Juvenile Idiopathic Arthritis
   h. Specialty Biological Agents for Ankylosing spondylitis
   i. Specialty Biological Agents for hidradenitis suppurativa
   j. Specialty Biological Agents for non-FDA approved indications
   k. Specialty Biological Agents for Rheumatoid arthritis
   l. Injectable/Infusible Osteoporosis Agents
m. Symlin (pramlintide)
n. Evista (raloxifene)
o. Ranexa (ranolazine)
p. Banzel (rufinamide)
q. Sabril (vigabatrin)
r. Sedative hypnotics
s. Vfend (voriconazole)
t. Restoril (temazepam)
u. Thalomid (thalidomide)
v. Gabitril (tiagabine)
w. Tasmar (tolcapone)
x. Topamax (topiramate) sprinkles
y. Tretinoin (Retin-A) gel or cream
z. Gattex (teduglitide)
aa. Injectable Bisphosphonates
bb. Lupron Depot/Depot-Ped (leuprolide)
c. Insulin Pens

VI) Interim Formulary Changes
   a. Interim Changes

VII) New Business
    a. Hepatitis C Recommendations
    b. New Product Review
    c. Pharmacy Sub Committee Meeting Minutes

VIII) Quarter 3 Reports
    a. Top 50 Drugs by Cost
    b. Top 100 PA Reviewed Drugs

IX) Public Comment

X) Next meeting- March 9, 2017

XI) Adjournment

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Anna Yang at 510-747-6155 or Ayang@alamedaalliance.org least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.